Search clinical trials for: relapsed /refractory Hodgkin lymphoma

Total 13537 results

Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Tianjin Medical University Cancer Institute and...
Nanjing Legend Biotech Co.

Not yet recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

B-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-Refractory

China
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Arvinas Inc.

Recruiting

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) | Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)

United States, Spain
Dren Bio
Novotech (Australia) Pty Limited

Recruiting

A Study of DR-0201 in Subjects With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

B-cell Non Hodgkin Lymphoma

Australia, Hong Kong, Korea, Republic of, Singapore, Taiwan
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Masonic Cancer Center, University of Minnesota

Not yet recruiting

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Autologous Stem Cell Transplant
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Beijing Tongren Hospital

Recruiting

Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

T-lymphoblastic Lymphoma | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

China
Zhejiang Genfleet Therapeutics Co., Ltd.

Recruiting

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

Large B-cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Roswell Park Cancer Institute

Recruiting

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell... and other conditions

United States
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Stanford University
The Leukemia and Lymphoma Society

Recruiting

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Hairy Cell Leukemia

United States
ImmunityBio, Inc.

Not yet recruiting

Study for Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma Refractory/ Relapsed
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Guangdong Ruishun Biotech Co., Ltd
Ruijin Hospital; Southern Medical University, China; Beijing GoBroad Hospital

Not yet recruiting

A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

B-cell Non-Hodgkin's Lymphoma
Peking University Cancer Hospital & Institute

Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

China
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Narendranath Epperla

Not yet recruiting

Pemigatinib for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma or Marginal Zone Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid... and other conditions

United States
Incyte Biosciences Italy S.r.l
Advice Pharma Group srl

Recruiting

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

DLBCL - Diffuse Large B Cell Lymphoma

Italy
The First Affiliated Hospital with Nanjing Medical...
Nanjing Legend Biotech Co.

Recruiting

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

China
Australasian Leukaemia and Lymphoma Group

Not yet recruiting

Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | DLBCL, Nos Genetic Subtypes | High Grade B-Cell Lymphoma, Not Otherwise Specified | Follicular Large Cell Lymphoma, Relapsed | Follicular Large Cell Lymphoma
Anhui Provincial Hospital
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
C. Babis Andreadis
Eli Lilly and Company; Genentech, Inc.; Adaptive Biotechnologies

Not yet recruiting

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Kite, A Gilead Company

Recruiting

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (JKART-1)

Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Japan
Astellas Pharma Global Development, Inc.

Recruiting

A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

B-cell Lymphoma

Australia
Qiu Lugui

Recruiting

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

Diffuse Large B-cell Lymphoma | Peripheral T Cell Lymphoma

China
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Taiwan, Spain, Korea, Republic of, Thailand, Italy, Malaysia, Turkey, Australia
University of Utah

Recruiting

Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies (PRODIGY)

Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma

United States
BGI, China
Shenzhen University General Hospital

Recruiting

Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T (GI-hNeoT-01)

T-cell Lymphoma

China
Hangzhou GluBio Pharmaceutical Co., Ltd.

Recruiting

A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Non-Hodgkin Lymphoma

China
M.D. Anderson Cancer Center
Genentech, Inc.; Kite, A Gilead Company

Recruiting

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

B Cell Lymphoma

United States
920th Hospital of Joint Logistics Support Force...
Shanghai PerHum Therapeutics Co., Ltd.

Recruiting

C752 for Refractory/Relapsed B Cell Non-Hodgkin Lymphoma

Lymphoma, B-Cell | CAR-T

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Chi-GVM Regimen for the Treatment of R/R PTCL

Relapsed/Refractory Peripheral T-cell Lymphoma

China
British Columbia Cancer Agency

Not yet recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

B-cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-Cell Leukemia | B-cell Acute Lymphoblastic Leukemia | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | High-grade B-cell Lymphoma

Canada
Shanghai Simnova Biotechnology Co.,Ltd.
Wuhan Union Hospital, China

Recruiting

F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

China
University of Chicago

Not yet recruiting

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Lymphoblastic Lymphoma | Acute Leukemia | Lymphoblastic Leukemia

United States
Navy General Hospital, Beijing

Recruiting

Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma

Refractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin Lymphoma

China
Mayo Clinic

Recruiting

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
Curon Biopharmaceutical (Shanghai) Co.,Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CN201

Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

China
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute

Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma | Non Hodgkin Lymphoma

China
Navy General Hospital, Beijing
Chinese PLA General Hospital

Recruiting

Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Angioimmunoblastic T Cell Lymphoma

Relapsed Angioimmunoblastic T-Cell Lymphoma | Refractory Angioimmunoblastic T-cell Lymphoma

China
Autolus Limited

Recruiting

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United Kingdom
BeBetter Med Inc

Recruiting

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

China
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
The First Affiliated Hospital of Xiamen University
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Recruiting

Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma

Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma | Refractory B-Cell Lymphoma

China

Search clinical trials for: relapsed /refractory Hodgkin lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations